FluidAI Medical, a Kitchener, Canada-based company leveraging artificial intelligence (AI) for postoperative patient monitoring, raised $15 million in Series A funding.
The round was led by SOSV and Graphene Ventures, with participation from other investors including Boutique Venture Partners, Threshold Impact, Cur8 Capital, and more.
SOSV is a venture capital firm that provides pre-seed, seed, venture and growth stage funding to startups in the technology sector. The company conducts seed accelerator programs in Asia and the United States of America.
Graohen Ventures is a venture capital firm focused on early-stage tech companies in enterprise software and consumer technology. The firm prefers to invest in high-growth tech companies in business to business, SaaS, health tech, fintech, blockchain, and mobile sectors. Founded in 2012 and is based in Palo Alto, California.
FluidAI Medical Use of Funds
The company plans to use the funds to expand into global markets, grow its team, invest in R&D, and introduce new AI-driven solutions for postoperative complications.
The funding will support the development of FluidAI's Stream™ Platform, which uses advanced sensors and an AI-driven algorithm to prompt surgeons to identify anastomotic leaks after surgery, helping improve clinical outcomes and reduce healthcare costs.
About FluidAI Medical
FluidAI (formerly known as NERv Technology Inc.) is a Canadian medical technology company that uses AI to aid with the early detection of postoperative leaks. From general to gastrointestinal surgeries, FluidAI's mission is to empower healthcare providers with data-driven solutions that improve patient outcomes and advance postoperative care.
Company: FluidAI Medical
Round: Series A
Funding Month: October 2023
Lead Investors: SOSV and Graphene Ventures
Additional Investors: Boutique Venture Partners, Threshold Impact, Cur8 Capital
Company Website: https://fluidai.md/
Software Category: Data-Driven Patient Recovery